biostudies-literatureBrunnert DDeutsche ForschungsgemeinschaftDepartment of BiotechnologyIndian Council of Medical Research1181https://www.ebi.ac.uk/biostudies/studies/S-EPMC10459547biostudies-literatureUnknown16(8)The <i>N</i>,<i>C</i>-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass specPharmaceuticals (Basel, Switzerland)Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate.PMC10459547BT/INF/22/SP44383/2021BT/HRD/01/59/2020KFO2166/9-7(234)2020/ECD-IISeupel RBach MSchlosser ABringmann GBargou RCKirner SChatterjee MGoyal PSchraud HKoster EFeineis DBrunnert DfalseAncistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate.The <i>N</i>,<i>C</i>-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass spec2023-01-01T00:00:00Z2023 Aug2026-04-08T13:39:54.765Z2025-04-19T10:18:04.881ZS-EPMC104595473763109510.3390/ph16081181